Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy (HCM). Strategic licensing deals with Sanofi and Bayer secure resources and focus US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback